Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05857358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia

Study acronym: XEROCELL
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 18, 2023 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Sep 2023 to Jan 2024 Primary completion date: Oct 2026 to Feb 2026 · Completion date: Apr 2027 to Aug 2027v3 Show 2 more changesShow less
    • Primary completion date: Oct 2026 to Feb 2026
    • Completion date: Apr 2027 to Aug 2027
  2. Secondary endpoints: details revised at 6 of 16 entries Eligibility criteria expanded, about 4 wordsv2 Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this study is to evaluate the tolerance and safety of autologous adipose-derived stromal vascular fraction injected in accessory salivary glands for treatment of autoimmune xerostomia in terms of adverse reactions through day 14 (D14).
Trial Details
NCT Number NCT05857358
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Xerostomia
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov